US Patent Issued to Intellia Therapeutics on Nov. 25 for "Compositions and methods for kallikrein (KLKB1) gene editing" (New Hampshire, Massachusetts Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,480,109, issued on Nov. 25, was assigned to Intellia Therapeutics Inc. (Cambridge, Mass.).

"Compositions and methods for kallikrein (KLKB1) gene editing" was invented by Shobu Odate (Arlington, Mass.) and Jessica Lynn Seitzer (Windham, N.H.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided."

The patent was filed on Jan. 17, 2025, under Application No. 19/028,692.

*For further information, including images, charts and tables, please visit: http://...